Direct answer:Animal medicines are marketed in the United States depending on their use, composition and product characteristics. New animal medicines usually involve NADA; ANADA for eligible imitation of new animal medicines; There may be a CNADA condition approval or Indexing path in a given case. FDA's application for approval of animal medicines is a different matter from the registration of pharmaceutical facilities, the commercial distribution of products, and the registration or listing of businesses cannot be approved as animal medicines.

Products used for animals may fall into animal medicine, animal food/feed, instruments or other regulatory categories. Uses and declarations are important elements of classification. Products such as pharmaceutical feed also involve specific rules, and it is recommended that FDA CVM be checked for regulatory positioning of specific products.

Differentiation of common paths

  • NADA:The new animal medicine application route is used to apply to the FDA for approval of the new animal drug.
  • ANADA:Applications for new animal medicines with acronyms are usually used for approved animal drug imitation products that are eligible.
  • CNADA:(b) The path of approval of the conditions, which is limited in scope and subject to the fulfilment of the legal conditions prior to ratification and renewal as required.
  • Indexing:The index path that may be applicable to a particular few uses and species of animals should not be considered a general alternative to the approval process.

Application and business information to be assessed separately

NADA/ANADA/CNADA deals with the route for the listing and approval of pharmaceutical products. The obligation to register facilities for the manufacture, repackaging or relabelling of medicines and the commercial distribution of products, etc., also needs to be judged separately on the basis of subject matter, business activity and product state. The specific path should be identified by the applicant holder in combination with evidence, quality of production, labelling and declaration strategy.

Information proposed for preparation by enterprises

  1. Animal species, uses, adaptives, routes of delivery and labelling claims.
  2. The relationship of the active ingredient, formulation type, specification, prescription and target product to the approved product.
  3. (b) Safety, effectiveness, quality control and production information; Animal drug consumption also requires an assessment of the relevant food safety issues.
  4. The United States applies for a holder, manufacturing facility, commissioning and commercial distribution arrangements.
  5. • Consulting, pre-submitted or declared plans and required evidence to the FDA CVM.

Common error

  • The animal drug NDC, facility registration or product listing is approved as FDA.
  • All animal products are thought to be taken from NADA, neglecting feed, equipment or exemptions.
  • NADA only is deemed applicable on the basis of an existing product name, without checking the reference product and statutory conditions.
  • The conditions for approval of CNADA are understood to be permanent approval or not to require annual renewal.

Official sources

Official page reconciliation date: 2026-10-27. Whether it belongs to animal medicines and the applicable routes are verified by specific product, use and corporate role.

Consultation drug compliance path.View pricing and order online ↗

Continue reading and preparation

Further consolidation of project information is availableScope of pharmaceutical compliance services; The scope, processing cycles and costs are shown on the corresponding service page.